PODD Stock Price Today (September 2026) — Insulet Corporation Analysis & Key Metrics 2026-09-03
Insulet Corporation (PODD) is trading at $150.58, up 1.65% today (as of September 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $171.91 (14.2% upside).
- Volatility remains elevated (30.68% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (23.50% YoY) alongside significant competitive pressures.
PODD Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Insulet Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $10.48B
P/E Ratio
Forward P/E: 19.28
Revenue Growth
Year over Year
Analyst Target
+14.2% upside potential
Key Investor Questions About PODD
What investors need to know before buying
Based on current market data, PODD presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 55.40)
- Fundamentals say: Caution warranted (high leverage concerns)
PODD's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PODD investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $948.40M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, PODD stock traded between $126.40 and $354.88—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 30.68% annualized volatility and β=0.60, the stock exhibits low sensitivity to market moves—making PODD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.
Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds
Insulet stock has fallen sharply over the past year, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and market multiples currently point to the shares trading below what those models suggest, while the broader valuation score still comes through as a mixed signal rather than a clear bargain. The share price is down 57.0% over the past year, which puts recent trading well below where many investors may have entered the stock. Future adoption of Insulet's...
Is Insulet (PODD) Undervalued On Lawsuit And Device Correction Risks?
Insulet (PODD) is back in focus after ongoing reminders about a securities class action lawsuit tied to alleged issues in its manufacturing controls and recent voluntary Medical Device Corrections disclosed in March and May 2026. At a share price of US$148.38, Insulet has seen short term resilience with a 7 day share price return of 3.73%. However, the 30 day share price return is down 10.26% and the 1 year total shareholder return has declined 56.98%, which points to fading momentum as...
MiniMed submits new patch pump for FDA clearance
The diabetes tech firm is preparing for the launch of new devices, including a tubeless insulin pump and a fully closed loop automated insulin delivery system.
Is Wall Street Bullish or Bearish on Insulet Stock?
Insulet has considerably underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.
Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?
McEvoy invested $162,217 at a weighted average price of $147.47, bringing total beneficial ownership to 23,735 shares valued at $3.52 million.
3 Mid-Cap Stocks with Competitive Advantages
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses will continue prospering by anchoring themselves in unique market segments.
5 Must-Read Analyst Questions From Insulet’s Q2 Earnings Call
Insulet’s second quarter was marked by strong revenue expansion but a sharp negative market reaction, as investors focused on emerging challenges in the company’s type 2 diabetes segment. While broad-based demand for Omnipod drove growth across both U.S. and international markets, CEO Ashley McEvoy acknowledged that lower-than-expected retention rates among new type 2 users weighed on results. McEvoy stated, “We should have identified the issue sooner,” signaling a more cautious approach to comm
Insulet Corporation’s (PODD) Wearable Pod Tech Finds New Frontier
Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]
Explore More Analysis for PODD
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Insulet Corporation
Insulet Corporation (PODD) is currently trading at $150.58. The RSI (14-day) is at 55.4, indicating neutral territory. Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $171.91 implies 14.2% upside from current levels. Volatility is moderate at 30.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Insulet Corporation (PODD): The trailing P/E ratio is 28.25, which is in line with broader market averages. The forward P/E is 19.28, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.44, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 7.34. Price-to-Sales is 3.42. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering PODD, the consensus price target is $171.91. This represents a 14.2% upside from the current price of $150.58. The range spans from a low target of $144.00 to a high target of $275.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Insulet Corporation (PODD) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Insulet Corporation (PODD) investors include: 1. Moderate volatility (30.7% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Insulet Corporation's (PODD) current debt and financial health profile: Total debt stands at $948.40M. The debt-to-equity ratio is 66.69, which is moderate and generally manageable for most companies. The current ratio is 2.48, indicating strong short-term liquidity. The quick ratio is 1.51. The company holds $534.90M in cash and equivalents. Free cash flow is positive at $236.90M, providing a cushion for debt servicing and shareholder returns.